Bicycle Therapeutics is developing a unique class of chemically synthesised medicines based on its proprietary bicyclic peptide (Bicycle®) product platform to address therapeutic needs unreachable with existing treatment modalities.
Bicycle’s internal focus is in oncology, where the company is developing targeted cytotoxics (Bicycle Toxin Conjugates), targeted innate immune activators and T-cell modulators for cancers of high unmet medical need. Bicycle is also working in other therapeutic areas through partnership: in respiratory, cardiovascular and metabolic disease with AstraZeneca, in haematology with Bioverativ, in ophthalmology with Thrombogenics and through Innovate UK in anti-infectives to realise the full therapeutic potential of the Bicycle technology.
Bicycles’ small size and exquisite targeting delivers rapid tumour penetration and retention while clearance rates and routes of elimination can be tuned to minimise exposure of healthy tissue and bystander toxicities.
The company’s unique intellectual property is based on the work initiated at the MRC Laboratory of Molecular Biology in Cambridge, U.K., by the scientific founders of the company, Sir Gregory Winter and Professor Christian Heinis.
Bicycle Therapeutics has its headquarters in Cambridge, U.K. with many key functions and members of its leadership team located in Boston, Massachusetts.
CIC point of contact: Michael Anstey